Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus jensenii LBV116 is a **vaginal-specific probiotic strain** of Lactobacillus jensenii, naturally found in the lower reproductive tract of women and comprising around 25% of a healthy vaginal microbiota[1][2][5]. It is specifically formulated to support and restore vaginal health, particularly by producing bioactive compounds—such as hydrogen peroxide—that help maintain the vagina’s natural defenses and inhibit pathogenic bacteria[1][5]. LBV116 aids in acidification and dominance of lactobacilli in the vaginal ecosystem, which is associated with lower risks of bacterial vaginosis, sexually transmitted infections, pelvic inflammatory disease, and preterm birth[1][2]. The strain is included in several clinically researched multi-strain oral probiotic blends, notably together with L. crispatus LBV88, L. rhamnosus LBV96, and L. gasseri LBV150N[1][2][5]. Clinical studies suggest oral administration can trend toward restoring healthy vaginal microbiota and improving Nugent scores in women with intermediate microbiota[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lactobacillus jensenii LBV116.